Crescent Biopharma合作伙伴科伦生物科技获中国NMPA批准CR-003 (SKB105)新药临床试验申请

美股速递
Jan 05

Crescent Biopharma Inc宣布,其合作伙伴科伦生物科技已正式获得中国国家药品监督管理局(NMPA)对其创新药物CR-003(研发代号SKB105)的新药临床试验申请批准。这一重要进展标志着该药物在中国进入临床开发阶段的关键一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10